Looking for biomarkers that predict recurrent GBM prognosis with the treatment of bevalbea monoantigens

Bevalbezumab is a monoclonal antibody for vascular endothelial growth factor (VEGF) and is commonly used in the treatment of patients with recurrent glioblastoma (GBM)Determining biomarkers that predict a patient's prognosis can help select the right caseThe Carboplatin and Bevacizumab in Recurrentizuma, GLIOblastoma, found no difference in overall survival (OS) in two groups of patients who were randomly treated with bevalzumab or EvacysizumabHowever, of the 122 patients, 5 (4%) had a survival time of more than 30 months, characterized by long-lasting reactive ness and longer survival timeLauren ROlafson of the Brain Cancer Treatment Biomarkers and Transformation Sats on Brain Cancer At the Prince of Wales Clinical College, University of New South Wales, Australia, and others in the CASE of the HIGHest survival and lowest survival rates in the CAT TRIALs, seeking biomarkers that predict the efficacy of bevalbeth resistance, published online in Journal of Clinical Science in September 2019the studythe retrospective study used 54 samples of the VAtest experiment and had sufficient biological samples to analyze the patient's paraffin encapsulation tissue, using immunohistochemistry (IHC) to detect 19 protein expressions associated with the treatment response of bevazumabAt the same time, MGMT promoter methylation is evaluatedAnd the use of whole genome sequencing (whole genome sequencing, WGS) to detect the DNA of tumor survivors who deviated from the survival mean and "prognosis."findingsfindings have found that there is no single protein expression level, including VEGF-A, that predicts THE PATIENT's OSWGS tests in survivors of "prognosis" and "prognosis" showed that patients with good prognosis obtained unique biomarkers on chromosome 19But a larger study sample is required to verify this findingmultivariate analysis suggests that only two biomarkers, c-met and MIG6, are associated with OSIn 46 c-MET-positive patients, the median total lifetime was 8 months, and the total lifetime median of 8 c-MET negative patients was 4.4 months, with significant differences between the two (p-0.01)C-MET positive patients with a six-month survival period accounted for 70 per cent and c-MET negative for 25 per cent The multivariate analysis shows that the negative regulation of MIG6 to EGFR is statistically significant The median OS in 44 MIG6 tumor-stained patients was 7.8 months, while the median OS in 10 MIG6-negative patients was 5.7 months (p-0.02) Of the 46 c-MET-positive patients, 36 (78%) were positive for MIG6 Of the overall study sample, 36 (67%) of the c-MET and MIG6 tested positive The samples of the subgroup of "prognosis difference" and "good prognosis" were both small, with 10 cases Only one "prognosis is good" survivor sitted in MGMT promoter methylation, indicating the importance of MGMT promoter methylation; conclusions
in summary, the study analyzed 19 potential protein biomarkers in tumor tissue in 54 cases of bebabezumab treatment in recurrent GBM patients and found that no candidate protein could be used as a marker for predicting good survival Using WGS analysis, the amplification of chromosome 19 appears promising, but requires a larger sample size for validation.